Eyepoint announces third consecutive positive DSMC recommendation for phase 3 wet AMD trials for Duravyu(TM), building confidence ahead of mid-2026 topline data

Published: 2026-05-14 07:51:32 ET EYPT

Published on 05/14/2026 at 07:51 am EDT